Search results
Results from the WOW.Com Content Network
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, [6] and in January 2018, the City of New ...
Janssen Pharmaceuticals was the first Western pharmaceutical company to set up a pharmaceutical factory in the People's Republic of China. [27] In 1976, Paul Janssen met Ma Haide (born George Shafik Hatem), a Lebanese-American doctor who had started working in China in 1933. After three days of meetings, the two agreed to bring a modernized ...
This page was last edited on 20 November 2024, at 19:57 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Technology companies in the New York City metropolitan area represent a significant and growing economic component of the New York metropolitan area, the most populous combined statistical area in the United States [1] and one of the most populous urban agglomerations in the world. [2] [3] New York is a top-tier global high technology hub. [4]
Catalent, Inc. (Catalent Pharma Solutions), a subsidiary of Novo Holdings A/S since 2024, is a multinational corporation headquartered in Somerset, New Jersey. It is a provider of drug delivery technologies, drug development , drug manufacturing , biologics , gene therapy , and consumer health products.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
In August 2023, Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1 billion [35] and Embark Biotech for up to $500 million. [36] In October 2023, the company announced it would acquire ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating ...
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. [7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan.